Gilead Sciences GILD Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $29.74B+1.0% | $29.44B+1.2% | $29.09B+0.8% | $28.86B+0.4% | $28.74B-0.1% | ||
| $6.14B-1.5% | $6.23B+0.7% | $6.19B-0.1% | $6.2B-0.7% | $6.24B-0.2% | ||
| $23.6B+1.7% | $23.21B+1.4% | $22.9B+1.0% | $22.67B+0.8% | $22.5B0.0% | ||
| 79.4%+0.5pp | 78.8%+0.1pp | 78.7%+0.2pp | 78.5%+0.2pp | 78.3%0.0pp | ||
| $5.97B+3.3% | $5.77B-1.9% | $5.89B-1.3% | $5.96B-0.2% | $5.98B-1.9% | ||
| $19.37B-0.3% | $19.42B+4.4% | $18.6B-10.6% | $20.81B+1.5% | $20.51B-24.3% | ||
| $10.37B+3.5% | $10.02B-4.5% | $10.49B+30.3% | $8.05B-2.1% | $8.22B+395% | ||
| 34.9%+0.8pp | 34%-2.0pp | 36.1%+8.2pp | 27.9%-0.7pp | 28.6%+22.8pp | ||
| $1.01B-2.0% | $1.03B+0.6% | $1.02B+1.8% | $1B+1.7% | $984M+0.6% | ||
| $1.36B+70.6% | $798M— | —— | —— | —— | ||
| $10.73B+9.5% | $9.8B-0.9% | $9.89B+37.3% | $7.2B+5.5% | $6.83B+889% | ||
| $1.62B+16.2% | $1.39B-21.7% | $1.78B+99.6% | $890M+3.5% | $860M+308% | ||
| $9.22B+8.3% | $8.51B+4.9% | $8.11B+28.5% | $6.31B+5.8% | $5.97B+1,143% | ||
| 31%+2.1pp | 28.9%+1.0pp | 27.9%+6.0pp | 21.9%+1.1pp | 20.8%+19.1pp | ||
| $7.34+8.4% | $6.77+5.0% | $6.45+28.5% | $5.02+5.7% | $4.75+1,184% | ||
| $7.42+8.3% | $6.85+5.2% | $6.51+28.9% | $5.05+5.9% | $4.77+1,189% | ||
| 5B-0.1% | 5B0.0% | 5B0.0% | 5B+0.1% | 5B+0.2% | ||
| 5B-0.1% | 5B-0.1% | 5B-0.1% | 5B0.0% | 5B0.0% | ||
| $877M-14.3% | $1.02B+111% | $484M-40.9% | $819M+2.9% | $796M-83.0% | ||
| $2.39B-0.1% | $2.39B0.0% | $2.39B0.0% | $2.39B+0.1% | $2.39B+0.1% | ||
| —— | —— | -$97M+92.7% | -$1.33B-0.9% | -$1.32B+28.4% | ||
| $366M-1.1% | $370M-1.3% | $375M-1.1% | $379M-1.3% | $384M+0.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $474M+2,357% | -$21M+92.6% | -$284M-104% | ||
| —— | —— | $706M+1,402% | $47M+20.5% | $39M-63.9% | ||
| -$1.59B+24.8% | -$2.11B— | —— | —— | —— | ||
| $865M-16.5% | $1.04B-9.0% | $1.14B+60.6% | $709M+17.4% | $604M+41.8% | ||
| $318M+2.3% | $311M-26.1% | $421M+283% | $110M-47.6% | $210M-18.9% | ||
| -$8.56B-10.5% | -$7.75B— | —— | —— | —— | ||
| -$2.61B+45.6% | -$4.79B-50.6% | -$3.18B+8.2% | -$3.47B-109% | -$1.66B+52.0% | ||
| $10.81B+7.9% | $10.02B+3.6% | $9.67B-2.0% | $9.87B-4.8% | $10.37B-4.3% | ||
| -$572M-19.2% | -$480M-76.5% | -$272M-1.1% | -$269M+17.2% | -$325M+7.9% | ||
| —— | —— | —— | —— | -$30M+48.3% | ||
| $1.61B-16.2% | $1.92B-5.9% | $2.04B+7.1% | $1.91B+28.9% | $1.48B+28.7% | ||
| $4.03B+0.7% | $4B+0.5% | $3.98B+0.6% | $3.96B+0.6% | $3.94B+0.5% | ||
| $4.18B+14.4% | $3.65B— | —— | —— | —— | ||
| $906M-15.3% | $1.07B+99.6% | $536M-42.9% | $939M-12.2% | $1.07B-77.9% | ||
| $576M+2.3% | $563M+11.5% | $505M+1.2% | $499M-4.4% | $522M-0.2% | ||
| $322M-21.1% | $408M-25.7% | $549M-0.2% | $550M+4.2% | $528M+25.1% | ||
| $91M+65.5% | $55M— | —— | —— | —— | ||
| -$443M-0.7% | -$440M-3.8% | -$424M-14.9% | -$369M-8.2% | -$341M-21.4% | ||
| $3.37B+295% | $854M— | —— | —— | —— | ||
| $2.79B+56.2% | $1.79B+0.1% | $1.79B-5.4% | $1.89B-49.4% | $3.73B+89.4% | ||
| $5.79B-0.1% | $5.8B-1.0% | $5.86B-0.8% | $5.91B+2.4% | $5.77B-2.4% | ||
| $29.74B+1.0% | $29.44B+1.2% | $29.09B+0.8% | $28.86B+0.4% | $28.74B-0.1% | ||
| $903M+1.0% | $894M+0.9% | $886M+1.6% | $872M+1.8% | $857M+2.6% | ||
| $10.37B+3.5% | $10.02B-4.5% | $10.49B+30.3% | $8.05B-2.1% | $8.22B+395% | ||
| $10.74B+3.3% | $10.39B-4.4% | $10.87B+28.9% | $8.43B-2.0% | $8.61B+321% | ||
| $10.74B+3.3% | $10.39B-4.4% | $10.87B+28.9% | $8.43B-2.0% | $8.61B+321% | ||
| 36.1%+0.8pp | 35.3%-2.1pp | 37.4%+8.1pp | 29.2%-0.7pp | 29.9%+22.8pp | ||
| $10.37B+3.5% | $10.02B-4.5% | $10.49B+30.3% | $8.05B-2.1% | $8.22B+395% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Gilead Sciences's revenue?
- Gilead Sciences (GILD) generated $29.7B in revenue over the trailing twelve months, up 3.5% year over year.
- Is Gilead Sciences profitable?
- Gilead Sciences reported $9.2B in net income over the trailing twelve months, a 31.0% net margin.
- What are Gilead Sciences's profit margins?
- Gross margin is 79.4% and operating margin is 34.9%, with a 31.0% net margin.
- What is Gilead Sciences's earnings per share?
- Gilead Sciences's diluted EPS over the trailing twelve months is $7.34.
- Where does Gilead Sciences's income statement data come from?
- Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
